Loading...
KORU Medical Systems Inc (KRMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive analyst sentiment with raised price targets, a meaningful catalyst expected with a 510K submission for oncology, and a strong revenue growth trend. While financials show some weaknesses in net income and EPS, the long-term growth potential and improving leverage make it a compelling opportunity.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 64.551, suggesting no overbought or oversold conditions. Moving averages are converging, and the stock is trading near resistance levels (R1: 4.936, R2: 5.097), with a current price of 5.03.

Analysts have raised price targets and maintained Buy ratings, with expectations of growth acceleration in
A 510K submission for oncology indication is expected by year-end, which could act as a significant catalyst.
Revenue increased by 27.17% YoY in Q3 2025.
Net income dropped by 50.79% YoY, and EPS decreased by 33.33% YoY.
Gross margin declined slightly by 3.88% YoY.
No significant hedge fund or insider trading activity to indicate strong institutional support.
In Q3 2025, revenue increased by 27.17% YoY to $10,402,163, showcasing strong growth. However, net income dropped by 50.79% YoY to -$777,966, and EPS fell by 33.33% YoY to -0.02. Gross margin also declined to 58.26%, down 3.88% YoY.
Analysts from Lake Street and Canaccord have raised price targets to $8 and $6, respectively, maintaining Buy ratings. Analysts expect growth acceleration in 2026 and improving leverage, which supports revenue upside and multiple expansion.